Geert-Jan Mulder

Geert-Jan is Managing Partner at Forbion and has a leading role in the Investment Team and the Portfolio. He is an experienced life sciences investor who led the firm’s successful investments and served on the Boards (sometimes also in an executive capacity) of portfolio companies: bluebird bio, (IPO on Nasdaq 2013), Acorda (IPO on Nasdaq 2006), PanGenetics (sold to Abbott in 2009), Transave (reverse-merger into Insmed in 2010), Exosome Diagnostics (sold to Bio-Techne), Promedior (sold to Roche in 2020), and KaNDy Therapeutics (sold to Bayer in 2020). Geert-Jan serves on the Board of several Forbion portfolio companies. In addition to his portfolio management activities, he works closely with management teams of various Forbion portfolio companies on clinical development strategies and regulatory matters, such as IND/ NDA filings, Special Protocol Approval (SPA), and US/EU Orphan designations for several products reflected by being a co-author of several Forbion and Forbion portfolio-related scientific publications.